A combination of a DNA-chimera siRNA against PLK-1 and zoledronic acid suppresses the growth of malignant mesothelioma cells in vitro.
Although novel agents effective against malignant mesothelioma (MM) have been developed, the prognosis of patients with MM is still poor. We generated a DNA-chimeric siRNA against polo-like kinase-1 (PLK-1), which was more stable in human serum than the non-chimeric siRNA. The chimeric PLK-1 siRNA inhibited MM cell proliferation through the induction of apoptosis. Next, we investigated the effects of zoledronic acid (ZOL) on MM cells, and found that ZOL also induced apoptosis in MM cells. Furthermore, ZOL augmented the inhibitory effects of the PLK-1 siRNA. In conclusion, combining a PLK-1 siRNA with ZOL treatment is an attractive strategy against MM.
Kawata
Eri
E
Department of Transfusion Medicine & Cell Therapy, Kyoto University Hospital, 54 Kawahara-cho Shogoin, Sakyo-ku, Kyoto 606-8507, Japan.
Ashihara
Eishi
E
Nakagawa
Yoko
Y
Kiuchi
Takahiro
T
Ogura
Mai
M
Yao
Hisayuku
H
Sakai
Kazuki
K
Tanaka
Ruriko
R
Nagao
Rina
R
Yokota
Asumi
A
Takeuchi
Miki
M
Kimura
Shinya
S
Hirai
Hideyo
H
Maekawa
Taira
T
D000818:Animals; D017209:Apoptosis / Q000187:drug effects / Q000235:genetics; D018797:Cell Cycle Proteins / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000235:genetics*; D048708:Cell Growth Processes / Q000187:drug effects / Q000235:genetics; D045744:Cell Line, Tumor; D002678:Chimera / Q000235:genetics; D003131:Combined Modality Therapy; D004247:DNA / Q000097:blood / Q000235:genetics*; D004164:Diphosphonates / Q000494:pharmacology*; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D008654:Mesothelioma / Q000201:enzymology / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000235:genetics*; D011518:Proto-Oncogene Proteins / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000235:genetics*; D034741:RNA, Small Interfering / Q000008:administration & dosage* / Q000097:blood / Q000235:genetics; D014162:Transfection; D000077211:Zoledronic Acid; D000097869:Polo-Like Kinase 1
D018797:Cell Cycle Proteins; D004247:DNA; D004164:Diphosphonates; D007093:Imidazoles; D017346:Protein Serine-Threonine Kinases; D011518:Proto-Oncogene Proteins; D034741:RNA, Small Interfering; D000077211:Zoledronic Acid; D000097869:Polo-Like Kinase 1